NeoGenomics Q2 2026: NGS Revenue Surge Drives a 49% EPS Beat
As seen on the 24/7 Wall St. homepage on July 28, 2026.
NeoGenomics cleared the bar with adjusted EPS of $0.05, crushing consensus by 49%, as a 26% surge in next-generation sequencing revenue drove average test prices up 12% to $515 and pushed margins 260 basis points higher. Management raised full-year guidance on the strength of this higher-value mix shift.
Continue ReadingShow less
NeoGenomics reported adjusted earnings per share of $0.05 for Q2 2026, well ahead of the $0.034 consensus estimate — a beat of roughly 49%. Revenue came in at $201.7 million, topping expectations of $197.0 million by about 2%. The quarter's outperformance was powered by a 26% jump in next-generation sequencing revenue, which pulled the average price per test up 12% to $515 and expanded margins by 260 basis points.
The NGS growth story is central to what investors are watching at NeoGenomics. Higher-value genomic tests carry better economics than the company's legacy menu, and this quarter showed that mix shift is beginning to meaningfully show up in the financials. That 260-basis-point margin expansion, achieved alongside double-digit volume-driven pricing gains, is the kind of operating leverage that tends to get analysts revisiting their models.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
Management responded to the quarter's momentum by raising full-year guidance. Looking back across recent quarters, results have been uneven — the company posted a loss of $0.20 per share in Q1 2025 against an estimated loss of $0.01 — making the current streak of profitable quarters, including $0.06 in Q4 2025 and now $0.05 in Q2 2026, a notable turn. Whether the NGS mix shift can sustain that trajectory into the back half of the year is the key question heading into Q3.
Mentioned: NEO